Characteristics and outcomes of patients with CFRD after QI efforts
| First chart review n=69 | Second chart review n=87 | p Value | |
|---|---|---|---|
| Age in years (SD) | 26.1 (11.7) | 25.1 (11.1) | 0.56 |
| Male, n (%) | 36 (52) | 45 (52) | 0.92 |
| Caucasian, n (%) | 66 (96) | 84 (96) | 0.89 |
| Height, cm (SD) | 163.41 (11.44) | 170.73 (57.44) | 0.012† |
| Height-for-age z-score (SD)‡ | 0.148 (1.75) | 1.26 (8.80) | 0.26§ |
| Weight, kg (SD) | 56.8 (13.5) | 58.9 (11.9) | <0.001† |
| BMI (SD)§ | 21.1 (3.1) | 21.4 (3.9) | 0.003† |
| Weight-for-age z-score (SD)¶ | −1.43 (0.76) | −0.84 (0.75) | <0.001† |
| FEV1% (SD)** | 65.6 (25.5) | 61.9 (24.0) | 0.008† |
*Weight change reported is uncorrected for age or growth.
†McNemar's paired t test. There were 63 patients with height measurement, 62 patients with weight, 62 patients with BMI, and 54 patients with FEV1% data from both chart reviews available for paired t tests. Significant changes in weight, weight-for-age z-score, BMI, and FEV1% persist when only adults are included or only patients without growth in height are included.
‡Height-for-age z-score is calculated using the method of Dibley et al17 and Lai et al,18 as we have performed previously for weight-for-age z-score.6
§When tested using t test, p=0.26, indicating that the height characteristics of the average patient followed at the study centers did not change during the study period. However, when testing patients participating in both years of the study, McNemar's paired t test detects that our group of study patients included adolescents who grew in stature during the study.
¶Weight-for-age z-score calculated as we have performed previously.6
**Annual maximum recorded value. The maximum value is chosen because it is the most reliably reproducible measurement.6
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1%, percent of predicted forced expiratory volume in 1 s; QI, quality improvement.